Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Davita Healthcare Partners Inc (DVA)

Davita Healthcare Partners Inc (DVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,888,943
  • Shares Outstanding, K 121,800
  • Annual Sales, $ 11,388 M
  • Annual Income, $ 810,980 K
  • 60-Month Beta 1.20
  • Price/Sales 0.85
  • Price/Cash Flow 7.07
  • Price/Book 4.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 1.29
  • Number of Estimates 7
  • High Estimate 1.37
  • Low Estimate 1.19
  • Prior Year 1.22
  • Growth Rate Est. (year over year) +5.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.30 +7.82%
on 06/26/20
82.96 -2.13%
on 07/07/20
-1.71 (-2.06%)
since 06/10/20
3-Month
71.70 +13.24%
on 04/24/20
89.39 -9.17%
on 06/08/20
+6.37 (+8.51%)
since 04/09/20
52-Week
53.51 +51.73%
on 08/28/19
90.15 -9.94%
on 02/12/20
+26.54 (+48.56%)
since 07/10/19

Most Recent Stories

More News
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis

Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.

DVA : 81.19 (+1.82%)
COO : 289.40 (-0.11%)
PDCO : 23.09 (+1.56%)
WST : 232.23 (-1.57%)
ZBH : 119.43 (+1.52%)
Top Ranked Growth Stocks to Buy for July 9th

Top Ranked Growth Stocks to Buy for July 9th

SFM : 24.35 (-0.69%)
PDCO : 23.09 (+1.56%)
KR : 33.44 (+2.08%)
DVA : 81.19 (+1.82%)
DVA or CHE: Which Is the Better Value Stock Right Now?

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA : 81.19 (+1.82%)
CHE : 473.47 (-0.32%)
3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest

Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.

DVA : 81.19 (+1.82%)
MYGN : 11.47 (+0.26%)
ADUS : 89.60 (-0.04%)
ANTM : 255.00 (unch)
ZBH : 119.43 (+1.52%)
Davita Inc Set to Possibly Pullback After Yesterday's Rally of 1.63%

Davita Inc (NYSE:DVA) traded in a range yesterday that spanned from a low of $80.51 to a high of $82.96. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $82.68...

DVA : 81.19 (+1.82%)
Look for Shares of Davita Inc to Potentially Pullback after Yesterday's 1.63% Rise

Davita Inc (NYSE:DVA) traded in a range yesterday that spanned from a low of $80.51 to a high of $82.96. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $82.68...

DVA : 81.19 (+1.82%)
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?

Is (DVA) Outperforming Other Medical Stocks This Year?

DVA : 81.19 (+1.82%)
Here's Why You Should Retain DaVita in Your Portfolio Now

Investor confidence is high on DaVita (DVA), thanks to solid prospects.

DGX : 116.82 (+0.84%)
DVA : 81.19 (+1.82%)
SRDX : 41.86 (+1.28%)
LH : 172.68 (-0.25%)
DaVita Kidney Care Appoints Chief Nursing Officer

, /PRNewswire/ --  recently announced as the company's chief nursing officer. Hale most recently served as the company's vice president of nursing, overseeing more than 18,000 nurses and 19,000 patient...

DVA : 81.19 (+1.82%)
Javier Rodriguez Joins Gilead Sciences' Board of Directors

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier Rodriguez has been appointed to the company's Board of Directors. Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune...

DVA : 81.19 (+1.82%)
GILD : 76.32 (+2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade DVA with:

Business Summary

DaVita Inc. is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a provider of kidney care, delivering dialysis services for chronic kidney failure and end stage renal disease primarily in the United States. HealthCare Partners manages and operates medical groups...

See More

Key Turning Points

2nd Resistance Point 82.66
1st Resistance Point 81.93
Last Price 81.19
1st Support Level 79.83
2nd Support Level 78.46

See More

52-Week High 90.15
Last Price 81.19
Fibonacci 61.8% 76.15
Fibonacci 50% 71.83
Fibonacci 38.2% 67.51
52-Week Low 53.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar